Study #2024-1872
NRG-GY032: A phase II study of tailored adjuvant therapy in POLE-mutated and p53-wildtype/NSMP early-stage endometrial cancer (RAINBO BLUE & TAPER)
MD Anderson Study Status
Enrolling
Treatment Agent
Description
This phase II trial tests how well tailoring therapy in post-surgery works in patients with low-risk endometrial cancer. The usual approach for patients with low-risk endometrial cancer is treatment with surgery. In this study, tissue that is removed as part of the surgical procedure is analyzed in the pathology laboratory to help guide the doctor to decide whether or not additional treatment such as radiation and or chemotherapy should be recommended.
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
Stage I Uterine Corpus Endometrial Stromal Sarcoma AJCC v8;Stage II Uterine Corpus Endometrial Stromal Sarcoma AJCC v8;Stage III Uterine Corpus Endometrial Stromal Sarcoma AJCC v8
Study phase:
Phase II
Physician name:
Ann Klopp
Department:
Radiation Oncology
For general questions about clinical trials:
1-844-982-1565
Help #EndCancer
Give Now
Donate Blood
Our patients depend on blood and platelet donations.
Shop MD Anderson
Show your support for our mission through branded merchandise.